Oxford BioDynamics PLC EpiSwitch used in diagnosis of canine lymphoma (9235Z)
15 Gennaio 2020 - 3:15PM
UK Regulatory
TIDMOBD
RNS Number : 9235Z
Oxford BioDynamics PLC
15 January 2020
15 January 2020
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics presents results of collaborative work
demonstrating first proof of principle for EpiSwitch(TM) biomarkers
in non-invasive diagnosis of canine lymphoma
-- Results of a study presented at the AACR Conference on
Advances in Liquid Biopsies demonstrate the utility of
EpiSwitch(TM) biomarkers for the diagnosis of canine lymphoma
-- Canine lymphoma accounts for 84% of blood cell malignancies and 24% of all tumours in dogs
Oxford BioDynamics Plc, a biotechnology company focused on the
discovery and development of biomarkers based on regulatory 3D
genome architecture, for use within the pharmaceutical and
biotechnology industry, announces that a study focused on the
diagnosis of B-cell lymphoma in dogs has been presented at the
American Association for Cancer Research (AACR) Conference on
Advances in Liquid Biopsies, which is taking place in Miami,
Florida, 13-16 January 2020.
On Tuesday 14 January, OBD presented a paper/poster at the
conference entitled: "Development and validation of diagnostic
biomarkers for B-cell lymphoma using EpiSwitch(TM) profiling of
whole blood: from humans to canines". The study was conducted in
collaboration with the University of Minnesota Department of
Veterinary Clinical Sciences, Animal Cancer Care and Research
Program, College of Veterinary Medicine and Masonic Cancer
Center.
OBD utilised its proprietary datasets of markers specific for
regulatory 3D genome architecture of lymphoma in humans, as
determined using EpiSwitch(TM), to see if these could be translated
from humans into dogs. OBD was able to generate a new biomarker
signature using whole blood from a cohort of dogs with lymphoma and
validate it on a second cohort. This biomarker signature was able
to correctly identify dogs with and without lymphoma with 80%
accuracy, 80% sensitivity, 80% specificity, 80% positive predictive
value and 80% negative predictive value.
The results of this study indicate that EpiSwitch(TM) biomarkers
can be successfully translated across species for related
pathologies and conditions. This highlights the potential
application of non-invasive EpiSwitch(TM) biomarkers in new
therapeutic developments, including within the veterinary
industry.
Alexandre Akoulitchev, Chief Scientific Officer of Oxford
BioDynamics, said:
"Our EpiSwitch(TM) technology has provided us with a great
wealth of data associated with lymphoma patients, and subsequently
allowed us to translate these insights into canines, where there is
a well-recognised unmet need. It is clear that the fundamentals of
3D genomics open up a new dimension for the application of
EpiSwitch(TM), particularly in veterinary science and animal
welfare.
Whilst as a Company we remain focused on human health, with the
quality and benefits of EpiSwitch(TM) well recognised in
immuno-oncology and neurodegenerative applications, this study
demonstrates that there is a wider potential of our technology to
ensure that the benefit of EpiSwitch(TM) is fully realised."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
FTI Consulting
Financial Public Relations
Adviser
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
The Company is headquartered in the UK and listed on the London
Stock Exchange's AIM under the ticker "OBD". For more information
please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFLFSVLSIELII
(END) Dow Jones Newswires
January 15, 2020 09:15 ET (14:15 GMT)
Grafico Azioni Oxford Biodynamics (LSE:OBD)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxford Biodynamics (LSE:OBD)
Storico
Da Apr 2023 a Apr 2024